| Company Name | Bayer Taiwan Co., Ltd. |
|---|---|
| Protocol Number | 20901 |
| Title of Study | XARETO / Xarelto® for the prevention of stroke and non-central nervous systemic embolism in non-valvular atrial fibrillation with REnal impairment in Taiwanese population. |
| Primary Objective | The primary objective of this study is to describe the safety of rivaroxaban regarding the incidence rate of major bleeding in NVAF patients with renal impairment in routine clinical practice. |
| Number of Sites | 11 |
| Period of Study | From：2019/11/01 to：2023/06/30 |
| Number of Patients | 500人 |
| IRB Approval Date | TPVGH 2020/02/07 NTUH 2020/02/24 CYCH 2020/03/06 CHiMei 2020/03/18/ KMUH 2020/03/06 CCH 2020/03/10 CMUH 2020/03/11 CGMH 2020/03/27 MMH 2020/04/01 NCKUH 2020/03/17 CHGH Pending |
| Publication Plan / Date | 2023 Q4 |
